

INVESTED IN

# MRI guidance

How Mammoth plans to add value and impact the world of medical imagery through this portfolio company.

# Why Mammoth Chose MRIguidance

## Impressive Team

MR physicist Peter Seevinck discovered a way to visualize bone with MRI scanners after being told it was impossible. Together with image scientist Marijn van Stralen, Peter further developed the BoneMRI technology at the University Medical Center Utrecht. In 2016 they partnered with med-tech entrepreneur Roel Raatgever, to found MRIguidance. Eva Hukshorn was added as Chief Financial and Operations Officer in 2021.



**Peter Seevinck**  
Co-Founder, CEO



**Marijn van Stralen**  
Co-Founder, CTO




**Eva Hukshorn**  
CFOO

## Ideal Product Market Fit

The Medical Imaging Informatics Market was valued at \$3.653 billion, and is expected to reach \$5.383 billion by 2022, supported by a CAGR of 5.6% (2016-2022).<sup>1</sup>


According to the experts from leading companies operating in this market, increases in the number of diagnostic imaging procedures and high prevalence of chronic diseases, decreases in cost of storage platforms, and improved healthcare ecosystems are some of the major factors driving market growth.<sup>1</sup>

<sup>1</sup> - <https://www.alliedmarketresearch.com/medical-imaging-informatics-market>



## First to Market

MRIguidance created the first medical imaging technique that visualizes both bone and soft tissue, without the need for hazardous radiation. For clinicians, BoneMRI works in the background in a seamless workflow without the need for new desktop applications.



# Portfolio Company



## Company Overview


MRIguidance is a spin-off company of UMC Utrecht that developed the medical imaging technique BoneMRI. The first research resulting in the proprietary BoneMRI technology dates back to 2013. This technology will mitigate the need for treatment-planning CT scans in the presence of MRI facilitated by MRI-based synthetic CT (sCT) which will revolutionize navigated spine surgery.

## Mammoth Impact

Mammoth Series 3 committed \$1,024,000 which brought the post-money valuation to \$16.5 million.

## Noteworthy

In orthopedics and neurology, radiologists and the treating physicians currently have to choose between an MRI scan for soft tissue and an X-ray based CT scan for bone information leading to suboptimal information for diagnosis and treatment planning, complex workflows and high healthcare costs. MRIguidance solves for all of this and brings a new ideal world to life through BoneMRI.



## Quick Look

### Founded

2016 - Utrecht, The Netherlands

### Founders

Peter Seevinck, CSO

Marijn van Stralen, CTO

Roel Raatgever, CEO

### Key Features

BoneMRI is a software solution that generates a CT-like image to complement the soft tissue images derived from an MRI scan. For clinicians, BoneMRI works in the background in a seamless workflow, without the need for new desktop applications.

- One stop shop for imaging
- Better diagnostic information
- No radiation

## Noteworthy (Continued)

**March 11, 2021**

Ghent University Hospital, Belgium was featured across several national publications due to their use of BoneMRI technology. The BoneMRI technique is now used as one of the standard scans in imaging of the pelvic region and hips there. The team in UZ Gent will continue to work with MRIguidance to apply BoneMRI to other regions in the body that preferably are not exposed to X-rays, including the spine.

**January 15, 2021**


In a proof of concept study, Dr. Marc Schröder and Victor Staartjes have shown that BoneMRI can be used for planning of a surgical procedure in the spine. The BoneMRI reconstructions were demonstrated to accurately visualize the bone anatomy in the lumbar spine, as compared to a conventional CT scan. The potential of BoneMRI for radiation-free surgical planning, near radiation-free intraoperative neuronavigation or robotic guidance, or in an adjunctive manner for diagnostic purposes were published in a peer-reviewed scientific journal Neurosurgical Focus.

## Product Highlight BoneMRI use in Adolescent Idiopathic Scoliosis (AIS) Treatment

MRIguidance will be the partner for delivering radiation free imaging of the spinal column of the scoliosis patients at the Technical University of Eindhoven (TUE) through a grant issued for the research of Professor Keita Ito. This research project is a collaboration with professor Castelein and dr. Seevinck of the University Medical Center Utrecht. Due to the absence of harmful radiation, BoneMRI will make it possible to monitor the development of the growing scoliotic spine which will for the first time allow research into the mechanobiology of AIS.

### ADVANCED ERC GRANT AWARDED

Advanced ERC grants are aimed at well-established top researchers, who have a recent high-level research track-record and profile which identifies them as leaders in their respective field. "With this generous award from the EU, we hopefully can provide a solution for this cruel disease, which causes disfiguration...", says Dr. Ito. Scoliosis (or adolescent idiopathic scoliosis (AIS), as its most common form is known) is a deformity of the spine that affects 2 to 3 percent of the population.



## MRIguidance Board Members




**Rutger Tulleken**

CEO/Entrepreneur with 20+ years experience in Life Sciences, Medical Devices and a strong knowledge of ICT. Expertise in leading turnaround and transformation processes and running and accelerating Life Science and ICT companies.



**René Castelein**

Professor of orthopedic surgery and chairman of the department of orthopedic surgery at the University Medical Center Utrecht, The Netherlands.



**Kornelis Poelstra**

Highly experienced Ortho- & Neuro Spine Surgeon with extensive Robotic Spine Surgery experience: co-developer of currently available Spine Robotic Systems.

## Important Legal Disclosure

This document is provided to potential investors to assist in evaluating participation in the opportunity described in it. This is not an offering document. Any offer of securities in a Mammoth Fund may only be made by delivery by Mammoth Scientific, LLC to the potential investor of definitive offering and legal documents. Mammoth Scientific, LLC is an investment adviser to venture capital funds that files as an exempt reporting adviser. Status as an exempt reporting adviser does not imply a certain level of skill or training. The securities offered by Mammoth Scientific, LLC have not been registered under the Securities Act of 1933, as amended, or the securities laws of any state, or jurisdiction, in reliance upon the exemptions from registration provided by the Securities Act and Regulation D Rule 506 (c) and comparable exemptions from registration provided by other applicable securities laws.

This document contains forward-looking statements or projections. These forward-looking statements can be identified by use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue,” or “believe,” or the negatives thereof or comparable terminology. Due to various risks and uncertainties, actual events, results or the actual performance of the Mammoth Fund’s portfolio companies may differ materially from those reflected or contemplated in such forward-looking statements. Nothing contained in this document may be relied upon as a guarantee, promise, assurance or a representation as to the projected results, future events or performance. Mammoth Scientific, LLC disclaims any obligation to update these forward-looking statements or projections or this document in general.

Investments in the Mammoth Funds will be suitable only for certain financially sophisticated investors who meet certain eligibility requirements, have no need for immediate liquidity in their investment, and can bear the risk of an investment in the Mammoth Funds for an extended period.

There is no guarantee that the investment objectives will be achieved. Moreover, the past performance of the investment team should not be construed as an indicator of future success. All prospective investors are encouraged to consult with their own legal, tax, financial and investment advisors. All investors should make their own determination of whether to make an investment based on their own independent evaluation. Additionally, this document does not include all material terms of the offering. This document is qualified entirely by the Fund’s Operating Agreement, offering documents and other legal and governance documents.

Mammoth Health & Tech Fund 1 invested \$500,569.60 of the \$1,024,000.

7.21.2021

PRIVATE COMPANIES AND PRIVATE INVESTMENTS INVOLVE UNIQUE RISKS. YOU SHOULD BE AWARE THAT YOU COULD LOSE YOUR ENTIRE INVESTMENT.